首页> 外文期刊>British Medical Journal >Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.
【24h】

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.

机译:高血压,微白蛋白尿和非胰岛素依赖型糖尿病患者双重阻断肾素-血管紧张素系统的随机对照试验:坎地沙坦和赖诺普利微白蛋白尿(CALM)研究。

获取原文
获取原文并翻译 | 示例
       

摘要

OBJECTIVES: To assess and compare the effects of candesartan or lisinopril, or both, on blood pressure and urinary albumin excretion in patients with microalbuminuria, hypertension, and type 2 diabetes. DESIGN: Prospective, randomised, parallel group, double blind study with four week placebo run in period and 12 weeks' monotherapy with candesartan or lisinopril followed by 12 weeks' monotherapy or combination treatment. SETTING: Tertiary hospitals and primary care centres in four countries (37 centres). PARTICIPANTS: 199 patients aged 30-75 years. INTERVENTIONS: Candesartan 16 mg once daily, lisinopril 20 mg once daily. MAIN OUTCOME MEASURES: Blood pressure and urinary albumin:creatinine ratio. RESULTS: At 12 weeks mean (95% confidence interval) reductions in diastolic blood pressure were 9.5 mm Hg (7.7 mm Hg to 11.2 mm Hg, P<0.001) and 9.7 mm Hg (7.9 mm Hg to 11.5 mm Hg, P<0.001), respectively, and in urinary albumin:creatinine ratio were 30% (15% to 42%, P<0.001) and 46% (35% to 56%, P<0.001) for candesartan and lisinopril, respectively. At 24 weeks the mean reduction in diastolic blood pressure with combination treatment (16.3 mm Hg, 13.6 mm Hg to 18.9 mm Hg, P<0. 001) was significantly greater than that with candesartan (10.4 mm Hg, 7.7 mm Hg to 13.1 mm Hg, P<0.001) or lisinopril (mean 10.7 mm Hg, 8.0 mm Hg to 13.5 mm Hg, P<0.001). Furthermore, the reduction in urinary albumin:creatinine ratio with combination treatment (50%, 36% to 61%, P<0.001) was greater than with candesartan (24%, 0% to 43%, P=0.05) and lisinopril (39%, 20% to 54%, P<0.001). All treatments were generally well tolerated. CONCLUSION: Candesartan 16 mg once daily is as effective as lisinopril 20 mg once daily in reducing blood pressure and microalbuminuria in hypertensive patients with type 2 diabetes. Combination treatment is well tolerated and more effective in reducing blood pressure.
机译:目的:评估和比较坎地沙坦或赖诺普利或两者对微蛋白尿,高血压和2型糖尿病患者血压和尿白蛋白排泄的影响。设计:前瞻性,随机,平行分组,双盲研究,在此期间进行了为期四周的安慰剂研究,并使用坎地沙坦或赖诺普利单药治疗12周,随后进行了12周单药治疗或联合治疗。地点:四个国家(37个中心)的三级医院和初级保健中心。参加者:199名30-75岁的患者。干预措施:坎地沙坦16 mg每天一次,赖诺普利20 mg每天一次。主要观察指标:血压和尿白蛋白:肌酐比值。结果:在12周的平均时间(95%置信区间),舒张压的下降幅度为9.5 mm Hg(7.7 mm Hg至11.2 mm Hg,P <0.001)和9.7 mm Hg(7.9 mm Hg至11.5 mm Hg,P <0.001) ),坎地沙坦和赖诺普利的尿白蛋白:肌酐比率分别为30%(15%至42%,P <0.001)和46%(35%至56%,P <0.001)。在第24周,联合治疗舒张压的平均降低幅度(16.3 mm Hg,13.6 mm Hg至18.9 mm Hg,P <0.001)显着大于坎地沙坦(10.4 mm Hg,7.7 mm Hg至13.1 mm)。 Hg,P <0.001)或赖诺普利(平均10.7 mm Hg,8.0 mm Hg至13.5 mm Hg,P <0.001)。此外,联合治疗时尿白蛋白:肌酐比值的降低(50%,36%至61%,P <0.001)大于坎地沙坦(24%,0%至43%,P = 0.05)和赖诺普利(39) %,20%至54%,P <0.001)。所有治疗通常耐受良好。结论:Candesartan每天一次16毫克与lisinopril每天一次20毫克在降低2型糖尿病高血压患者的血压和微量白蛋白尿方面一样有效。组合治疗耐受性良好,并且在降低血压方面更有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号